Genetic Technologies Total Assets 2006-2021 | GENE

Genetic Technologies total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Genetic Technologies Annual Total Assets
(Millions of US $)
2021 $17
2020 $10
2019 $2
2018 $5
2017 $9
2016 $10
2015 $17
2014 $6
2013 $9
2012 $17
2011 $9
2010 $7
2009 $14
2008 $22
2007 $18
2006 $34
2005 $22
Genetic Technologies Quarterly Total Assets
(Millions of US $)
2021-06-30 $17
2020-06-30 $10
2019-12-31 $3
2019-06-30 $2
2018-12-31 $3
2018-06-30 $5
2017-12-31 $7
2017-06-30 $9
2016-12-31 $12
2016-06-30 $10
2015-12-31 $12
2015-06-30 $17
2014-12-31 $3
2014-06-30 $6
2013-12-31 $14
2013-06-30 $9
2012-12-31 $13
2012-06-30 $17
2011-12-31 $16
2011-06-30 $9
2010-12-31 $12
2010-06-30 $7
2009-12-31 $12
2009-06-30 $14
2008-12-31 $15
2008-06-30 $22
2007-12-31 $25
2007-06-30 $18
2006-12-31 $22
2006-06-30 $34
2005-12-31 $29
2005-06-30 $22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.037B $0.000B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $119.040B 7.52
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.569B 21.29
Biohaven Pharmaceutical Holding (BHVN) United States $7.352B 0.00
Arcus Biosciences (RCUS) United States $3.077B 0.00
Emergent Biosolutions (EBS) United States $2.374B 8.53
Myovant Sciences (MYOV) United Kingdom $1.569B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.534B 0.00
Zymeworks (ZYME) Canada $0.936B 0.00
SQZ Biotechnologies (SQZ) United States $0.369B 0.00
Ambrx Biopharma (AMAM) United States $0.352B 0.00
Enzo Biochem (ENZ) United States $0.169B 16.57